CD47/SIPRα Blockade Bioassay Service
Blocking the CD47-SIPRα Interaction is Significant for Cancer Therapy.
CD47 is a "don't eat me" signal commonly overexpressed on tumor cells, enabling them to evade immune detection and destruction. CD47 functions through binding to SIRPα expressed on phagocytic cells to inhibit their ability to engulf and eliminate the tumor cells. Recent therapeutic strategies have focused on blocking the CD47–SIRPα interaction to activate phagocytic cells to enhance their anti-tumor activity. This approach shows potential in cancer treatment by reactivating the immune system to effectively target and eliminate malignant cells.
Fig.1 CD47-SIRPα interaction leads to the phosphorylation of two tyrosine residues from ITIM in the intracellular domain of SIRPα.1, 3
CD47/SIPRα Blockade Bioassay at Creative Biolabs
As a leading company in the tumor research field, Creative Biolabs delivers a CD47/SIPRα blockade bioassay for global customers to serve as an invaluable tool for cancer therapeutics development.
Our CD47/SIRPα blockade bioassay offers a cutting-edge, cell-based bioluminescent reporter system designed to precisely evaluate the potency and stability of Fc-silent or Fc-null ligands and antibodies capable of binding and blocking SIRPα-CD47 interactions. This assay leverages the fact that the CD47-SIRPα interaction suppresses TCR-mediated luminescence. When candidate compounds effectively disrupt this interaction, TCR activation is restored, resulting in luminescence detectable by a luminometer.
To ensure the highest levels of reliability and accuracy in this cell-based bioassay, we provide engineered cell lines—namely, CD47 aAPC Cells and SIRPα Effector Cells—that are optimized for performance. Moreover, our team of specialists is ready to create customized solutions that precisely match your unique requirements. Simultaneously, our robust platform and professional team empower our confidence in the rapid delivery of high-quality results for each of our customers.
Fig.2 The workflow of our CD47/SIRPα blockade bioassay.
Hot Products at Creative Biolabs
At the same time, we also supply a variety of high-quality ready-to-use products, such as EasyMeasure™ SIRPα/CD47 Blockade Bioassay Kit, Fc-Null (CAT#: ZL-0624-WR3) and EasyMeasure™ SIRPα/CD47 Blockade Bioassay Kit, Fc-Dependent (CAT#: ZL-0624-WR4) for customers to choose from for effective and efficient projects advancement.
Attractive Advantages
- High reproducibility.
- Short turnaround time: as fast as 2 weeks.
- Free positive and negative controls.
- Stringent documentation and project management.
- Customized one-stop solutions.
Case Study
Case 1: Considering the critical role of the SIRPα-CD47 axis in preventing tumor phagocytosis, there has been a growing emphasis on targeting this pathway in cancer therapies. Recently, numerous treatments have been developed that effectively block the SIRPα-CD47 interaction to enhance antitumor immune responses. Here are several notable SIRPα/CD47 blockade strategies and immunotherapies that have entered clinical practice.
Fig.3 Effective combinations of SIRPα/CD47 blockade and antitumor immunotherapy.2, 4
Q & A
Q: What are the requirements for CD47/SIPRα blockade assay?
A: To ensure optimal outcomes, we request that customers provide fundamental details including sample numbers, quantities, concentrations, endotoxin levels, purity, and other relevant information. For more comprehensive guidance, you can reach out to our technical support team. Additionally, if you have particular needs, our experts are happy to tailor specialized solutions to your specifications.
Please contact us in your free time with your challenging projects to discuss for further collaboration. We are eager to hear from you.
References
- Chen, Can, et al. "Targeting CD47 as a novel immunotherapy for breast cancer." Frontiers in oncology 12 (2022): 924740.
- Jia, Xiao, et al. "CD47/SIRPα pathway mediates cancer immune escape and immunotherapy." International journal of biological sciences 17.13 (2021): 3281.
- under Open Access license CC BY 4.0, without modification.
- under Open Access license CC BY 4.0. The original image was modified by extracting and using only a part, and the title was changed to "Effective combinations of SIRPα/CD47 blockade and antitumor immunotherapy".
For Research Use Only.